CompletedPHASE1, PHASE2NCT02012985
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OxThera
- Principal Investigator
- Bernd Hoppe, MD PhDUniversitätsklinikum Bonn, Dept of Paediatric Nephrology
- Intervention
- Oxabact OC5 capsules(biological)
- Enrollment
- 28 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2013 – 2015
Study locations (8)
- Hôpital Robert-Debré, Néphrologie Pédiatrique, Paris, Cedex 19, France
- Hôpital des Enfants, Centre de référence maladies rénales rares du Sud-Ouest (SORARE), CHU de Bordeaux, Bordeaux, France
- Hôpital Femme Mère Enfant, Lyon - Paediatric Dept, Lyon, France
- Hôpital Necker-Enfants Malades,Centre de référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France
- Universitätsklinikum Bonn, Dept of Paediatric Nephrology, Bonn, Germany
- Birmingham Children's Hospital NHS Foundation Trust - Dept of Nephrology, Birmingham, United Kingdom
- Royal Free Hospital -UCL Centre for Nephrology, London, United Kingdom
- Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Collaborators
FP7-SME-2013 Research for the benefit of SMEs program
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02012985 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company